This Biotech Stock Is Jumping 25% After Getting an FDA Boost

Core Viewpoint - Novocure's stock surged by 25% following the FDA's approval of its Optune Pax product for treating specific pancreatic cancers, which was based on successful results from a Phase 3 clinical trial [1] Company Summary - Novocure received FDA approval for its Optune Pax product, which is intended for patients with certain types of pancreatic cancer [1] - The approval was granted after the product met its primary endpoint in a Phase 3 clinical trial, indicating a significant milestone for the company [1]